A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 15, 349-355
Abstract
Purpose: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone). Patients and methods: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients’ clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography. Results: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients’ myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone. Conclusion: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication.Keywords
This publication has 27 references indexed in Scilit:
- Etiology of cardiovascular disease in patients with schizophrenia: current perspectivesNeuropsychiatric Disease and Treatment, 2015
- Incidence of Cardiovascular Outcomes and Diabetes Mellitus Among Users of Second-Generation AntipsychoticsThe Journal of Clinical Psychiatry, 2013
- Drugs and dilated cardiomyopathies: a case/noncase study in the French PharmacoVigilance DatabaseBritish Journal of Clinical Pharmacology, 2010
- Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of SchizophreniaNeurotherapeutics, 2009
- Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes FederationDiabetic Medicine, 2006
- Metabolic Syndrome in Patients With SchizophreniaThe Journal of Clinical Psychiatry, 2003
- Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of OlanzapineJournal of Clinical Psychopharmacology, 2003
- Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining studyBMJ, 2001
- Cardiovascular Risk Factors for People with Mental IllnessAustralian & New Zealand Journal of Psychiatry, 2001
- Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophyJACC, 1995